The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. | The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,

The Biden administration on Friday released the next round of prescription drugs selected for Medicare price negotiations, including Ozempic — the blockbuster diabetes drug that’s also used for weight loss.